Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Pharmacokinetics of [14C]-Benzo[a]pyrene (BaP) in humans: Impact of Co-Administration of smoked salmon and BaP dietary restriction.

Hummel JM, Madeen EP, Siddens LK, Uesugi SL, McQuistan T, Anderson KA, Turteltaub KW, Ognibene TJ, Bench G, Krueger SK, Harris S, Smith J, Tilton SC, Baird WM, Williams DE.

Food Chem Toxicol. 2018 May;115:136-147. doi: 10.1016/j.fct.2018.03.003. Epub 2018 Mar 5.

PMID:
29518434
2.

COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin.

Wang F, Zhang H, Ma AH, Yu W, Zimmermann M, Yang J, Hwang SH, Zhu D, Lin TY, Malfatti M, Turteltaub KW, Henderson PT, Airhart S, Hammock BD, Yuan J, de Vere White RW, Pan CX.

Mol Cancer Ther. 2018 Feb;17(2):474-483. doi: 10.1158/1535-7163.MCT-16-0818. Epub 2017 Dec 28.

PMID:
29284644
3.

Maternal exposure to an environmentally relevant dose of triclocarban results in perinatal exposure and potential alterations in offspring development in the mouse model.

Enright HA, Falso MJS, Malfatti MA, Lao V, Kuhn EA, Hum N, Shi Y, Sales AP, Haack KW, Kulp KS, Buchholz BA, Loots GG, Bench G, Turteltaub KW.

PLoS One. 2017 Aug 9;12(8):e0181996. doi: 10.1371/journal.pone.0181996. eCollection 2017.

4.

A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer.

Wang SS, Zimmermann M, Zhang H, Lin TY, Malfatti M, Haack K, Turteltaub KW, Cimino GD, de Vere White R, Pan CX, Henderson PT.

Int J Cancer. 2017 Aug 1;141(3):604-613. doi: 10.1002/ijc.30747. Epub 2017 May 15.

PMID:
28437852
5.

Mass Spectrometric Characterization of an Acid-Labile Adduct Formed with 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and Albumin in Humans.

Wang Y, Villalta PW, Peng L, Dingley K, Malfatti MA, Turteltaub KW, Turesky RJ.

Chem Res Toxicol. 2017 Feb 20;30(2):705-714. doi: 10.1021/acs.chemrestox.6b00426. Epub 2017 Jan 18.

6.

Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.

Zimmermann M, Wang SS, Zhang H, Lin TY, Malfatti M, Haack K, Ognibene T, Yang H, Airhart S, Turteltaub KW, Cimino GD, Tepper CG, Drakaki A, Chamie K, de Vere White R, Pan CX, Henderson PT.

Mol Cancer Ther. 2017 Feb;16(2):376-387. doi: 10.1158/1535-7163.MCT-16-0381. Epub 2016 Nov 30.

7.

Use of Accelerator Mass Spectrometry in Human Health and Molecular Toxicology.

Enright HA, Malfatti MA, Zimmermann M, Ognibene T, Henderson P, Turteltaub KW.

Chem Res Toxicol. 2016 Dec 19;29(12):1976-1986. Epub 2016 Oct 11. Review.

8.

Human Microdosing with Carcinogenic Polycyclic Aromatic Hydrocarbons: In Vivo Pharmacokinetics of Dibenzo[def,p]chrysene and Metabolites by UPLC Accelerator Mass Spectrometry.

Madeen EP, Ognibene TJ, Corley RA, McQuistan TJ, Henderson MC, Baird WM, Bench G, Turteltaub KW, Williams DE.

Chem Res Toxicol. 2016 Oct 17;29(10):1641-1650. Epub 2016 Sep 9.

9.

Quantifying Carbon-14 for Biology Using Cavity Ring-Down Spectroscopy.

McCartt AD, Ognibene TJ, Bench G, Turteltaub KW.

Anal Chem. 2016 Sep 6;88(17):8714-9. doi: 10.1021/acs.analchem.6b02054. Epub 2016 Aug 9.

10.

Disposition of the Dietary Mutagen 2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline in Healthy and Pancreatic Cancer Compromised Humans.

Malfatti MA, Kuhn EA, Turteltaub KW, Vickers SM, Jensen EH, Strayer L, Anderson KE.

Chem Res Toxicol. 2016 Mar 21;29(3):352-8. doi: 10.1021/acs.chemrestox.5b00495. Epub 2016 Mar 8.

11.

An Interface for the Direct Coupling of Small Liquid Samples to AMS.

Ognibene TJ, Thomas AT, Daley PF, Bench G, Turteltaub KW.

Nucl Instrum Methods Phys Res B. 2015 Oct 15;361:173-177. Epub 2015 May 28.

12.

Operation of the "Small" BioAMS Spectrometers at CAMS: Past and Future Prospects.

Ognibene TJ, Haack KW, Bench G, Brown TA, Turteltaub KW.

Nucl Instrum Methods Phys Res B. 2015 Oct 15;361:54-57. Epub 2015 May 26.

13.

Model-Based, Closed-Loop Control of PZT Creep for Cavity Ring-Down Spectroscopy.

McCartt AD, Ognibene TJ, Bench G, Turteltaub KW.

Meas Sci Technol. 2014 Sep 1;25(9). pii: 095201.

14.

Use of microdosing and accelerator mass spectrometry to evaluate the pharmacokinetic linearity of a novel tricyclic GyrB/ParE inhibitor in rats.

Malfatti MA, Lao V, Ramos CL, Ong VS, Turteltaub KW.

Antimicrob Agents Chemother. 2014 Nov;58(11):6477-83. doi: 10.1128/AAC.03300-14. Epub 2014 Aug 18.

15.

Accelerator mass spectrometry detection of beryllium ions in the antigen processing and presentation pathway.

Tooker BC, Brindley SM, Chiarappa-Zucca ML, Turteltaub KW, Newman LS.

J Immunotoxicol. 2015 Apr-Jun;12(2):181-7. doi: 10.3109/1547691X.2014.917748. Epub 2014 Jun 16.

16.

2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) is selectively toxic to primary dopaminergic neurons in vitro.

Griggs AM, Agim ZS, Mishra VR, Tambe MA, Director-Myska AE, Turteltaub KW, McCabe GP, Rochet JC, Cannon JR.

Toxicol Sci. 2014 Jul;140(1):179-89. doi: 10.1093/toxsci/kfu060. Epub 2014 Apr 9. Erratum in: Toxicol Sci. 2014 Oct;141(2):560.

17.

Directly coupled high-performance liquid chromatography-accelerator mass spectrometry measurement of chemically modified protein and peptides.

Thomas AT, Stewart BJ, Ognibene TJ, Turteltaub KW, Bench G.

Anal Chem. 2013 Apr 2;85(7):3644-50. doi: 10.1021/ac303609n. Epub 2013 Mar 20.

18.

Determining the pharmacokinetics and long-term biodistribution of SiO2 nanoparticles in vivo using accelerator mass spectrometry.

Malfatti MA, Palko HA, Kuhn EA, Turteltaub KW.

Nano Lett. 2012 Nov 14;12(11):5532-8. doi: 10.1021/nl302412f. Epub 2012 Oct 17.

19.

Identification and elucidation of the biology of adverse events: the challenges of safety assessment and translational medicine.

Turteltaub KW, Davis MA, Burns-Naas LA, Lawton MP, Clark AM, Reynolds JA.

Clin Cancer Res. 2011 Nov 1;17(21):6641-5. doi: 10.1158/1078-0432.CCR-11-1106.

20.

A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance.

Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, Grimminger PP, Danenberg KD, Beckett L, de Vere White RW, Turteltaub KW, Pan CX.

Int J Cancer. 2011 Sep 15;129(6):1425-34. doi: 10.1002/ijc.25814. Epub 2011 Mar 4.

21.

Yeast dynamic metabolic flux measurement in nutrient-rich media by HPLC and accelerator mass spectrometry.

Stewart BJ, Navid A, Turteltaub KW, Bench G.

Anal Chem. 2010 Dec 1;82(23):9812-7. doi: 10.1021/ac102065f. Epub 2010 Nov 9.

22.

Towards biomarker-dependent individualized chemotherapy: exploring cell-specific differences in oxaliplatin-DNA adduct distribution using accelerator mass spectrometry.

Hah SS, Henderson PT, Turteltaub KW.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2448-51. doi: 10.1016/j.bmcl.2010.03.020. Epub 2010 Mar 7.

23.

Statistical analysis of variation in the human plasma proteome.

Corzett TH, Fodor IK, Choi MW, Walsworth VL, Turteltaub KW, McCutchen-Maloney SL, Chromy BA.

J Biomed Biotechnol. 2010;2010:258494. doi: 10.1155/2010/258494. Epub 2010 Jan 14.

24.

Recent advances in biomedical applications of accelerator mass spectrometry.

Hah SS, Henderson PT, Turteltaub KW.

J Biomed Sci. 2009 Jun 17;16:54. doi: 10.1186/1423-0127-16-54. Review. Erratum in: J Biomed Sci. 2009;16:111. Henderson, Paul T [added]; Turteltaub, Kenneth W [added].

25.

NASA Radiation Biomarker Workshop, September 27-28, 2007.

Straume T, Amundson SA, Blakely WF, Burns FJ, Chen A, Dainiak N, Franklin S, Leary JA, Loftus DJ, Morgan WF, Pellmar TC, Stolc V, Turteltaub KW, Vaughan AT, Vijayakumar S, Wyrobek AJ.

Radiat Res. 2008 Sep;170(3):393-405. doi: 10.1667/RR1382.1.

PMID:
18763867
26.

Single sample extraction protocol for the quantification of NAD and NADH redox states in Saccharomyces cerevisiae.

Sporty JL, Kabir MM, Turteltaub KW, Ognibene T, Lin SJ, Bench G.

J Sep Sci. 2008 Oct;31(18):3202-11. doi: 10.1002/jssc.200800238.

27.

Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations.

Hah SS, Sumbad RA, de Vere White RW, Turteltaub KW, Henderson PT.

Chem Res Toxicol. 2007 Dec;20(12):1745-51. Epub 2007 Nov 15.

PMID:
18001055
28.

Tamoxifen forms DNA adducts in human colon after administration of a single [14C]-labeled therapeutic dose.

Brown K, Tompkins EM, Boocock DJ, Martin EA, Farmer PB, Turteltaub KW, Ubick E, Hemingway D, Horner-Glister E, White IN.

Cancer Res. 2007 Jul 15;67(14):6995-7002.

29.

Measurement of 7,8-dihydro-8-oxo-2'-deoxyguanosine metabolism in MCF-7 cells at low concentrations using accelerator mass spectrometry.

Hah SS, Mundt JM, Kim HM, Sumbad RA, Turteltaub KW, Henderson PT.

Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11203-8. Epub 2007 Jun 25.

30.

The urinary metabolite profile of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine is predictive of colon DNA adducts after a low-dose exposure in humans.

Malfatti MA, Dingley KH, Nowell-Kadlubar S, Ubick EA, Mulakken N, Nelson D, Lang NP, Felton JS, Turteltaub KW.

Cancer Res. 2006 Nov 1;66(21):10541-7.

31.

Statistical analysis of the experimental variation in the proteomic characterization of human plasma by two-dimensional difference gel electrophoresis.

Corzett TH, Fodor IK, Choi MW, Walsworth VL, Chromy BA, Turteltaub KW, McCutchen-Maloney SL.

J Proteome Res. 2006 Oct;5(10):2611-9.

PMID:
17022632
32.

Inflammation and atrophy precede prostatic neoplasia in a PhIP-induced rat model.

Borowsky AD, Dingley KH, Ubick E, Turteltaub KW, Cardiff RD, Devere-White R.

Neoplasia. 2006 Sep;8(9):708-15.

33.

A novel 14C-postlabeling assay using accelerator mass spectrometry for the detection of O6-methyldeoxy-guanosine adducts.

Tompkins EM, Farmer PB, Lamb JH, Jukes R, Dingley K, Ubick E, Turteltaub KW, Martin EA, Brown K.

Rapid Commun Mass Spectrom. 2006;20(5):883-91.

PMID:
16470516
34.

Accelerator mass spectrometry for biomedical research.

Brown K, Dingley KH, Turteltaub KW.

Methods Enzymol. 2005;402:423-43. Review.

PMID:
16401518
35.

Statistical challenges in the analysis of two-dimensional difference gel electrophoresis experiments using DeCyder.

Fodor IK, Nelson DO, Alegria-Hartman M, Robbins K, Langlois RG, Turteltaub KW, Corzett TH, McCutchen-Maloney SL.

Bioinformatics. 2005 Oct 1;21(19):3733-40. Epub 2005 Aug 9.

PMID:
16091413
36.

Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations.

DeGregorio MW, Dingley KH, Wurz GT, Ubick E, Turteltaub KW.

Cancer Chemother Pharmacol. 2006 Feb;57(3):335-42. Epub 2005 Jul 27.

PMID:
16047147
37.

Measurement of beryllium in biological samples by accelerator mass spectrometry: applications for studying chronic beryllium disease.

Chiarappa-Zucca ML, Finkel RC, Martinelli RE, McAninch JE, Nelson DO, Turteltaub KW.

Chem Res Toxicol. 2004 Dec;17(12):1614-20.

PMID:
15606137
38.
39.

Serum protein profile alterations in hemodialysis patients.

Langlois RG, Trebes JE, Dalmasso EA, Ying Y, Davies RW, Curzi MP, Colston BW Jr, Turteltaub KW, Perkins J, Chromy BA, Choi MW, Murphy GA, Fitch JP, McCutchen-Maloney SL.

Am J Nephrol. 2004 Mar-Apr;24(2):268-74. Epub 2004 Mar 19.

PMID:
15031630
40.

The formation of AFB(1)-macromolecular adducts in rats and humans at dietary levels of exposure.

Cupid BC, Lightfoot TJ, Russell D, Gant SJ, Turner PC, Dingley KH, Curtis KD, Leveson SH, Turteltaub KW, Garner RC.

Food Chem Toxicol. 2004 Apr;42(4):559-69.

PMID:
15019179
41.

Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry.

Martin EA, Brown K, Gaskell M, Al-Azzawi F, Garner RC, Boocock DJ, Mattock E, Pring DW, Dingley K, Turteltaub KW, Smith LL, White IN.

Cancer Res. 2003 Dec 1;63(23):8461-5.

42.

The effects of coffee on enzymes involved in metabolism of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in rats.

Turesky RJ, Richoz J, Constable A, Curtis KD, Dingley KH, Turteltaub KW.

Chem Biol Interact. 2003 Jun 15;145(3):251-65.

PMID:
12732453
43.

Benzene metabolism in rodents at doses relevant to human exposure from urban air.

Turteltaub KW, Mani C.

Res Rep Health Eff Inst. 2003 Feb;(113):1-26; discussion 27-35.

PMID:
12675491
44.
45.

Attomole detection of in vivo protein targets of benzene in mice: evidence for a highly reactive metabolite.

Williams KE, Carver TA, Miranda JJ, Kautiainen A, Vogel JS, Dingley K, Baldwin MA, Turteltaub KW, Burlingame AL.

Mol Cell Proteomics. 2002 Nov;1(11):885-95.

46.

Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA.

Boocock DJ, Brown K, Gibbs AH, Sanchez E, Turteltaub KW, White IN.

Carcinogenesis. 2002 Nov;23(11):1897-901.

PMID:
12419838
47.

Attomole quantitation of protein separations with accelerator mass spectrometry.

Vogel JS, Grant PG, Buchholz BA, Dingley K, Turteltaub KW.

Electrophoresis. 2001 Jun;22(10):2037-45. Review.

PMID:
11465504
48.

Solution structure of the 2-amino-1- methyl-6-phenylimidazo[4,5-b]pyridine C8-deoxyguanosine adduct in duplex DNA.

Brown K, Hingerty BE, Guenther EA, Krishnan VV, Broyde S, Turteltaub KW, Cosman M.

Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8507-12. Epub 2001 Jul 3.

49.

Synthesis and spectroscopic characterization of site-specific 2-amino-1-methyl-6-phenylimidazo.

Brown K, Guenther EA, Dingley KH, Cosman M, Harvey CA, Shields SJ, Turteltaub KW.

Nucleic Acids Res. 2001 May 1;29(9):1951-9.

50.

Quantitation of benzo[a]pyrene-DNA adducts by postlabeling with 14C-acetic anhydride and accelerator mass spectrometry.

Goldman R, Day BW, Carver TA, Mauthe RJ, Turteltaub KW, Shields PG.

Chem Biol Interact. 2000 Jun 1;126(3):171-83.

PMID:
10862816

Supplemental Content

Loading ...
Support Center